Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Fosaprepitant is converted to aprepitant, which selectively antagonises substance P at NK1 receptors in the central nervous system and gastrointestinal pathways involved in emesis.
Indications / reported uses
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin-based regimens, in combination with other antiemetics
Prevention of nausea and vomiting associated with moderately emetogenic chemotherapy where covered by the specific product regimen
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fosaprepitant PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fosaprepitant Permitted Daily Exposure (PDE) report (the Fosaprepitant PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fosaprepitant Occupational Exposure Limit (OEL) report (the Fosaprepitant OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.